<p>Apogee Therapeutics, Inc.（纳斯达克股票代码：APGE - 获取免费报告）股票周三在盘中交易中下跌了 2.7%。该股票的最低交易价为 36.88 美元，最后交易价为 37.16 美元。在盘中交易期间，共有 85,240 股股票交易，较平均交易量 55,863 股下降了 85%。该股票此前收盘价为 38.21 美元。</p>
<p>获取 <strong>Apogee Therapeutics</strong> 警报：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>IPO 观察 2024：哪些新股将上市？</li>
</ul>
<p>一些股票分析师已经就该公司发布了报告。Stifel Nicolaus 将 Apogee Therapeutics 的目标股价从 46.00 美元上调至 95.00 美元，并在 3 月 5 日星期二的研究报告中给予该公司 “买入” 评级。美国银行在 5 月 10 日星期五的研究报告中开始对 Apogee Therapeutics 进行覆盖。他们对该股票发行了 “买入” 评级，并设定了 80.00 美元的目标股价。Guggenheim 将 Apogee Therapeutics 的价格目标从 44.00 美元上调至 91.00 美元，并在 3 月 5 日星期二的研究报告中给予该股票 “买入” 评级。Wedbush 在 5 月 13 日星期一的研究报告中重申了 “表现优异” 评级，并设定了 87.00 美元的价格目标。最后，Jefferies 金融集团将 Apogee Therapeutics 的价格目标从 37.00 美元上调至 75.00 美元，并在 3 月 6 日星期三的研究报告中给予该股票 “买入” 评级。根据 MarketBeat.com，共有八位投资分析师对该股票进行了买入评级，目前该公司的平均评级为 “买入”，平均目标股价为 73.00 美元。</p>
<p><strong>查看我们关于 APGE 的最新报告</strong></p>
<h2>Apogee Therapeutics 股票下跌 1.9%</h2>
<p>该股票的五十日移动平均价为 45.85 美元，两百日移动平均价为 44.48 美元。</p>
<p>Apogee Therapeutics（纳斯达克股票代码：APGE - 获取免费报告）最近发布了其截至 5 月 13 日星期一的财报。公司报告季度每股收益为（0.64）美元，低于分析师对（0.60）美元的共识预期。分析师预计，Apogee Therapeutics, Inc.本财年将发布-2.64 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近买入和卖出了 Apogee Therapeutics 的股票。EntryPoint Capital LLC 在第一季度将其在 Apogee Therapeutics 的持仓增加了 44.7%。EntryPoint Capital LLC 现在拥有该公司股票 1,997 股，价值 133,000 美元，较上一季度增加了 617 股。Kennedy Capital Management LLC 在第一季度收购了 Apogee Therapeutics 的新头寸，价值 212,000 美元。Ameritas Investment Partners Inc.在第一季度将其在 Apogee Therapeutics 的持股增加了 111.2%。Ameritas Investment Partners Inc.现在拥有该公司股票 4,126 股，价值 274,000 美元，较上一季度增加了 2,172 股。Principal Financial Group Inc.在第一季度收购了 Apogee Therapeutics 的新头寸，价值 339,000 美元。最后，Virtu Financial LLC 在第一季度收购了 Apogee Therapeutics 的新头寸，价值 362,000 美元。该股票的 79.04% 由机构投资者和对冲基金持有。</p>
<h2>关于 Apogee Therapeutics（获取免费报告）</h2>
<p>Apogee Therapeutics, Inc.及其子公司经营一家生物技术公司，开发用于治疗特应性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相关炎症和免疫疾病指标的生物制剂。该公司主要开发 APG777，用于 AD 的皮下（SQ）延长半衰期单克隆抗体（mAb）；以及 APG808，用于 COPD 的 SQ 延长半衰期 mAb。</p>
<h2>精选故事</h2>
<ul>
<li>我们比 Apogee Therapeutics 更喜欢的五只股票</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>AbbVie 股票：投资者购买的完美机会</li>
<li>低 PE 增长股：开启投资机会</li>
<li>忘记 NVIDIA：超微计算机股领先于动量</li>
<li>什么是 WallStreetBets 以及他们瞄准哪些股票？</li>
<li>GitLab 股票反弹：其复苏内幕故事</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ [突破] “贩毒者” 治愈脑疾？（来自市场背后）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Apogee Therapeutics 股票？</h2>
<p>在考虑购买 Apogee Therapeutics 股票之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票... Apogee Therapeutics 不在名单上。</p>
<p>尽管 Apogee Therapeutics 目前在分析师中具有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

APGE

<p>Apogee Therapeutics（纳斯达克股票代码：APGE）股价在午间交易中下跌了 2.7%。该股票最低交易价为$36.88，最后交易价为$37.16。平均交易量下降了 85%，成交量为 85,240 股。该股票的 50 天移动平均价为$45.85，200 天移动平均价为$44.48。该公司报告了低于预期的季度盈利结果。多位分析师将该股票评为 “买入”，平均目标价为$73.00</p>

<p>Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) shares traded down 2.7% during mid-day trading on Wednesday . The stock traded as low as $36.88 and last traded at $37.16. 85,240 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 558,863 shares. The stock had previously closed at $38.21.</p>
<div class="lb-trans"><p>Apogee Therapeutics, Inc.（纳斯达克股票代码：APGE - 获取免费报告）股票周三在盘中交易中下跌了 2.7%。该股票的最低交易价为 36.88 美元，最后交易价为 37.16 美元。在盘中交易期间，共有 85,240 股股票交易，较平均交易量 55,863 股下降了 85%。该股票此前收盘价为 38.21 美元。</p>
</div><p>Get <strong>Apogee Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Apogee Therapeutics</strong> 警报：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<ul>
<li>IPO watch 2024: Which new stocks will hit the market?</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
<ul>
<li>IPO 观察 2024：哪些新股将上市？</li>
</ul>
</div><p>Several equities analysts have issued reports on the company. Stifel Nicolaus lifted their target price on Apogee Therapeutics from $46.00 to $95.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Bank of America initiated coverage on Apogee Therapeutics in a research note on Friday, May 10th. They issued a &#34;buy&#34; rating and a $80.00 target price on the stock. Guggenheim boosted their price target on Apogee Therapeutics from $44.00 to $91.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 5th. Wedbush restated an &#34;outperform&#34; rating and set a $87.00 price target on shares of Apogee Therapeutics in a research note on Monday, May 13th. Finally, Jefferies Financial Group boosted their price target on Apogee Therapeutics from $37.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, March 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and an average target price of $73.00.</p>
<div class="lb-trans"><p>一些股票分析师已经就该公司发布了报告。Stifel Nicolaus 将 Apogee Therapeutics 的目标股价从 46.00 美元上调至 95.00 美元，并在 3 月 5 日星期二的研究报告中给予该公司 “买入” 评级。美国银行在 5 月 10 日星期五的研究报告中开始对 Apogee Therapeutics 进行覆盖。他们对该股票发行了 “买入” 评级，并设定了 80.00 美元的目标股价。Guggenheim 将 Apogee Therapeutics 的价格目标从 44.00 美元上调至 91.00 美元，并在 3 月 5 日星期二的研究报告中给予该股票 “买入” 评级。Wedbush 在 5 月 13 日星期一的研究报告中重申了 “表现优异” 评级，并设定了 87.00 美元的价格目标。最后，Jefferies 金融集团将 Apogee Therapeutics 的价格目标从 37.00 美元上调至 75.00 美元，并在 3 月 6 日星期三的研究报告中给予该股票 “买入” 评级。根据 MarketBeat.com，共有八位投资分析师对该股票进行了买入评级，目前该公司的平均评级为 “买入”，平均目标股价为 73.00 美元。</p>
</div><p><strong>View Our Latest Report on APGE</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 APGE 的最新报告</strong></p>
</div><h2>Apogee Therapeutics Trading Down 1.9 %</h2>
<div class="lb-trans"><h2>Apogee Therapeutics 股票下跌 1.9%</h2>
</div><p>The stock has a fifty day moving average of $45.85 and a 200 day moving average of $44.48.</p>
<div class="lb-trans"><p>该股票的五十日移动平均价为 45.85 美元，两百日移动平均价为 44.48 美元。</p>
</div><p>Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.04). Analysts expect that Apogee Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apogee Therapeutics（纳斯达克股票代码：APGE - 获取免费报告）最近发布了其截至 5 月 13 日星期一的财报。公司报告季度每股收益为（0.64）美元，低于分析师对（0.60）美元的共识预期。分析师预计，Apogee Therapeutics, Inc.本财年将发布-2.64 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently bought and sold shares of APGE. EntryPoint Capital LLC increased its position in shares of Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock valued at $133,000 after buying an additional 617 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $212,000. Ameritas Investment Partners Inc. lifted its stake in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock valued at $274,000 after purchasing an additional 2,172 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $339,000. Finally, Virtu Financial LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $362,000. 79.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近买入和卖出了 Apogee Therapeutics 的股票。EntryPoint Capital LLC 在第一季度将其在 Apogee Therapeutics 的持仓增加了 44.7%。EntryPoint Capital LLC 现在拥有该公司股票 1,997 股，价值 133,000 美元，较上一季度增加了 617 股。Kennedy Capital Management LLC 在第一季度收购了 Apogee Therapeutics 的新头寸，价值 212,000 美元。Ameritas Investment Partners Inc.在第一季度将其在 Apogee Therapeutics 的持股增加了 111.2%。Ameritas Investment Partners Inc.现在拥有该公司股票 4,126 股，价值 274,000 美元，较上一季度增加了 2,172 股。Principal Financial Group Inc.在第一季度收购了 Apogee Therapeutics 的新头寸，价值 339,000 美元。最后，Virtu Financial LLC 在第一季度收购了 Apogee Therapeutics 的新头寸，价值 362,000 美元。该股票的 79.04% 由机构投资者和对冲基金持有。</p>
</div><h2>About Apogee Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Apogee Therapeutics（获取免费报告）</h2>
</div><p>Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.</p>
<div class="lb-trans"><p>Apogee Therapeutics, Inc.及其子公司经营一家生物技术公司，开发用于治疗特应性皮炎（AD）、哮喘、慢性阻塞性肺病（COPD）及相关炎症和免疫疾病指标的生物制剂。该公司主要开发 APG777，用于 AD 的皮下（SQ）延长半衰期单克隆抗体（mAb）；以及 APG808，用于 COPD 的 SQ 延长半衰期 mAb。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Apogee Therapeutics</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Forget NVIDIA: Super Micro Computer Stock Leads in Momentum</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>GitLab Stock Rebounds: The Inside Story of Its Comeback</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们比 Apogee Therapeutics 更喜欢的五只股票</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>AbbVie 股票：投资者购买的完美机会</li>
<li>低 PE 增长股：开启投资机会</li>
<li>忘记 NVIDIA：超微计算机股领先于动量</li>
<li>什么是 WallStreetBets 以及他们瞄准哪些股票？</li>
<li>GitLab 股票反弹：其复苏内幕故事</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ [Breakthrough] The &#34;Drug Smuggler&#34; Curing Brain Disease? (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ [突破] “贩毒者” 治愈脑疾？（来自市场背后）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjQx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8641&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apogee Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Apogee Therapeutics 股票？</h2>
</div><p>Before you consider Apogee Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Apogee Therapeutics 股票之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票... Apogee Therapeutics 不在名单上。</p>
</div><p>While Apogee Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Apogee Therapeutics 目前在分析师中具有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Apogee Therapeutics（纳斯达克代码：APGE）股价下跌 2.7%